New pill for fatty liver enters early human testing
NCT ID NCT07462455
First seen Apr 01, 2026 · Last updated Apr 24, 2026 · Updated 4 times
Summary
This early-stage trial tests a new oral drug called ACT500 in 24 adults with metabolic fatty liver disease (MASLD). The main goal is to check safety and how the drug moves through the body. Participants take one pill daily, and doctors monitor for side effects and measure drug levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tsinghua Changgeng Hospital
Beijing, China
Contact
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Contact
-
The First Affiliated Hospital of Xiamen University
Xiamen, China
Contact
-
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, China
Contact
Conditions
Explore the condition pages connected to this study.